Novartis announced today additional results from the SCULPTURE study showing that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx (secukinumab) reported no impact of skin disease on their quality of life through 5 years, as described by the Dermatology Life Quality Index (DLQI) 0/1 response (72.7% at Year 1 and 65.5% at Year 5) – a questionnaire used to evaluate the impact of skin disease on a patient’s quality of life. These data were presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California.
Study findings also show absolute PASI ≤1/≤2/≤3 scores at Year 1 (58.6%, 67.9% and 74.1%, respectively) were sustained to Year 5 (53.3%, 66.4% and 75.4%, respectively); as observed analysis1. Absolute PASI scores can provide an indication of disease severity after treatment. Achievement of an absolute PASI score lower than 2 or 3 has been proposed as an indication of treatment success.
Psoriasis is not simply a cosmetic problem, but a persistent, chronic (long-lasting), and sometimes distressing disease, which can affect even the smallest aspects of people’s lives on a daily basis.“There is a link between achieving skin clearance and improved quality of life, and proper management of psoriasis should address both the physical symptoms of the disease and its impact on patients’ daily lives,” said Craig Leonardi, MD, Adjunct Professor of Dermatology at St. Louis University School of Medicine. “Results from the SCULPTURE study show treatment with Cosentyx can deliver both over the long-term. It’s encouraging to see such improvements in DLQI responses and absolute PASI scores below 3 through 5 years.”
“Patients with psoriasis are looking for a treatment that not only achieves clear skin, but also addresses the negative impact psoriasis has on their lives,” said Shreeram Aradhye, Chief Medical Officer and Global Head, Medical Affairs, Novartis Pharmaceuticals. “We are excited by this new evidence, showing two thirds of psoriasis patients reporting no impact on their quality of life at 5 years when treated with Cosentyx, and the possibilities this offers patients.”
The most common adverse events included nasopharyngitis, upper respiratory tract infection and headache, consistent with those reported in the core study and previous Phase III studies.
Cosentyx is the first and only fully human IL-17A inhibitor approved to treat ankylosing spondylitis (AS), psoriatic arthritis (PsA) and moderate to severe plaque psoriasis. To date, Cosentyx has been prescribed to more than 140,000 patients worldwide since launch.
Filed Under: Drug Discovery
